Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

Status unconfirmed · Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.

Key facts

Study ID

NCT00054496

Run by

The Cleveland Clinic

People needed

73

Starts

2002-08-01

Last updated by the study team

2014-01-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.